21.10.2014 • News

Solvay Confirms Growth Outlook for 2014

Solvay has reiterated its confidence that 2014 will show a good operating performance, in line with its mid-term growth objectives.

Prior to reporting results for the first three quarters of 2014 on Nov. 13, the Brussels-based chemical producer has confirmed its earlier guidance, saying it expects high single-digit year-on-year REBITDA growth in 2014 at prevailing foreign exchange rates.

Solvay's full year 2014 results and the comparison with 2013 will be restated to reflect the sale of its Eco Services' sulfuric acid production and regeneration business to affiliates of CCMP Capital Advisors.

The deal is expected to be completed in the fourth quarter of this year.

Based on these changes, Solvay's consolidated REBITDA for 2013 and for the first six months of 2014 will be restated at €1.6 billion and € 911 million respectively, compared to €1.7 billion and € 953 million reported before the discontinuation of Eco Services.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.